Average Weight Gain on Mirtazapine: 1.5 kg
Based on the highest quality guideline evidence, mirtazapine is associated with an average weight gain of 1.5 kg. 1
Quantitative Evidence from Guidelines
The 2015 Endocrine Society Clinical Practice Guideline on Pharmacological Management of Obesity provides the most robust systematic review data available. Their commissioned systematic review demonstrated that mirtazapine causes an average weight gain of 1.5 kg 1. This figure comes from pooled analysis of controlled trials and represents the mean weight change attributable to the medication.
FDA-Approved Drug Label Data
The FDA label for mirtazapine provides additional context on the clinical significance of this weight gain 2:
- In U.S. controlled clinical studies, 7.5% of mirtazapine-treated patients gained ≥7% of body weight, compared to 0% for placebo
- Appetite increase was reported in 17% of patients on mirtazapine versus 2% on placebo
- In long-term open-label studies, 8% of patients discontinued mirtazapine specifically due to weight gain
- In pediatric trials (8 weeks, 15-45 mg/day), 49% of patients gained at least 7% of body weight, compared to 5.7% on placebo
Important Clinical Context
Time Course and Magnitude
Research studies reveal that weight gain with mirtazapine:
- Begins early: Significant weight gain is evident after the first week of treatment 3
- Continues over time: Mean weight gain of 2.4 kg at 4 weeks 3 and 3 kg at 6 weeks 4 in research settings
- Primarily affects fat mass: The weight gain is predominantly increased body fat (visceral and subcutaneous), not fluid retention 4, 5
Mechanism of Weight Gain
The weight gain occurs through multiple pathways 4, 3, 5:
- Increased appetite (17% of patients) 2
- Upregulation of orexigenic hormones (ghrelin, neuropeptide Y)
- Downregulation of anorexigenic hormones (leptin initially, though leptin eventually rises as fat mass increases)
- H1 receptor antagonism (similar mechanism to weight-gaining antipsychotics)
Comparative Context
Among antidepressants, mirtazapine ranks as one of the highest for weight gain potential 6:
- Higher weight gain: Amitriptyline (1.8 kg), mirtazapine (1.5 kg), paroxetine
- Weight neutral: Citalopram, escitalopram, sertraline (long-term), venlafaxine
- Weight loss: Bupropion (-1.3 kg), fluoxetine (-1.3 kg)
Clinical Pitfalls and Monitoring
Common mistake: Failing to warn patients about weight gain before starting therapy. The 2015 Endocrine Society guideline specifically recommends shared decision-making with quantitative estimates of expected weight effects 1.
Key monitoring points:
- Weigh patients at baseline and regularly during treatment
- The FDA label notes that weight gain can be substantial enough to warrant discontinuation in 8% of patients 2
- Be particularly vigilant in pediatric patients, where weight gain is more pronounced (49% gain ≥7% body weight) 2
- Consider metabolic effects: While glucose homeostasis typically remains stable 4, monitor cholesterol (15% of patients have increases ≥20% above normal) and triglycerides (6% exceed 500 mg/dL) 2
When weight gain is problematic: Consider switching to weight-neutral alternatives (escitalopram, sertraline) or weight-loss promoting options (bupropion) if clinically appropriate for the patient's depression subtype 1, 6.